Equities

Cenra Inc

3716:TAI

Cenra Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)38.00
  • Today's Change0.10 / 0.26%
  • Shares traded110.53k
  • 1 Year change-19.49%
  • Beta--
Data delayed at least 20 minutes, as of Nov 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments489852946
Total Receivables, Net2,4592,5542,321
Total Inventory2,5852,4812,266
Prepaid expenses------
Other current assets, total515234
Total current assets5,5835,9395,567
Property, plant & equipment, net4,5414,2994,252
Goodwill, net------
Intangibles, net182216
Long term investments2,3032,2322,613
Note receivable - long term------
Other long term assets11183105
Total assets12,86512,82312,787
LIABILITIES
Accounts payable864850799
Accrued expenses553708602
Notes payable/short-term debt1,6301,3081,097
Current portion long-term debt/capital leases554136
Other current liabilities, total291392274
Total current liabilities3,3933,3002,807
Total long term debt1,7521,8031,902
Total debt3,4383,1523,034
Deferred income tax151185172
Minority interest383734
Other liabilities, total99105118
Total liabilities5,4325,4305,033
SHAREHOLDERS EQUITY
Common stock2,9812,9812,981
Additional paid-in capital648648647
Retained earnings (accumulated deficit)3,9793,8733,617
Treasury stock - common(28)(28)(28)
Unrealized gain (loss)(31)4.87631
Other equity, total(117)(86)(94)
Total equity7,4327,3937,754
Total liabilities & shareholders' equity12,86512,82312,787
Total common shares outstanding297297297
Treasury shares - common primary issue0.830.830.83
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.